PremiumThe FlyProcessa Pharmaceuticals jumps 28% after Phase 2 study update Processa: First patient dosed in Phase 2 clinical trial of NGC-Cap for MBC Processa Pharmaceuticals reports Q2 EPS ($1.01) vs. ($1.94) last year PremiumCompany AnnouncementsProcessa Pharmaceuticals Welcomes New CFO Russell Skibsted Processa Pharmaceuticals appoints Skibsted as CFO Processa announces results from preliminary eval of Phase 1b trial with NGC-Cap PremiumThe FlyProcessa presents two abstracts at AACR 2024 including data on NGC-Cap trial Processa Pharmaceuticals’ Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks PCSA Earnings this Week: How Will it Perform?